27% jump in 5 sessions! This small-cap stock is flying high; check Q1 numbers

The stock is part of the BSE small-cap universe.

On Friday, the company released its financial results for the quarter ended June 30, 2025 (Q1 FY26).

The company, in its press release, said that its consolidated revenue from operations for the quarter under review was ₹84.10 crore, up 2% YoY. Its operating profit, which is also known as EBITDA, or earnings before interest, taxes, depreciation, and amortisation, stood at ₹26.18 crore, up 33% from ₹19.73 crore. EBITDA margin surged 7% YoY to 31%.

Profit after tax (PAT) rallied an impressive 131% YoY to ₹17.29 crore against ₹7.49 crore in the year-ago quarter. Profit margin jumped 12% to 21%. Earnings per share, or EPS (not annualised), stood at ₹20.33, up 131% YoY.

The company said consolidated results include operations of subsidiaries from Nepal and Tanzania.

Hester’s consolidated divisional product sales reached ₹84.08 crore, marking a 2% growth. Net profit surged by 131%, driven by a turnaround in Hester Africa’s performance and improved cost control.

Hester Nepal contributed a net profit of ₹1.91 crore in Q1 FY26, compared to ₹2.72 crore in Q1 FY25, on a topline of ₹5.07 crore, versus ₹6.32 crore in the same period last year. The subsidiary continued to maintain a healthy presence in its market, executing key institutional orders and sustaining operational momentum.

Hester Africa delivered a net profit of ₹5.50 crore, marking a significant turnaround from a loss of ₹5 crore in Q1 FY25, on a topline of ₹17.22 crore, up from ₹2.79 crore in the corresponding period last year.

"This performance was supported by improved commercial execution and wider market penetration. With a stabilised manufacturing base in Tanzania and increased access to regional demand, Hester Africa is now well-positioned to scale its presence across the continent. The company is also expanding its footprint in high-priority markets to support future growth," the company said.

Animal Healthcare Division

In Q1 FY26, the division recorded a 33% decline in sales, primarily due to timing delays in key government immunisation programs for PPR and lumpy skin disease, in which Hester’s PPR and goat pox vaccines, respectively, are widely used and have been delayed. These programs, although delayed, are expected to roll out in the subsequent quarters.

"Despite this temporary dip, the division maintained stable demand for the therapeutic products. Additionally, alternate products were introduced to mitigate earlier regulatory challenges and ensure product continuity in key markets," the company said.

Poultry Healthcare Division

The Poultry Healthcare Division recorded a 2% growth in Q1 FY26, led by robust demand for key vaccines, particularly for Newcastle Disease and Marek’s Disease.

New feed supplements and disinfectants launched last year are gaining acceptance, with an anticipated stronger contribution in the upcoming quarters. The division also expanded its technical support initiatives and customer partnerships, reinforcing its position in a competitive market, it said.

About Hester Biosciences Limited

Hester Biosciences Limited is one of India’s leading animal health companies, manufacturing vaccines and health products since 1997. Hester has two divisions:

• Poultry Healthcare division;
• Animal Healthcare division (which includes Ruminants and pet health segments)